In recent years, chimeric antigen receptor (CAR) T-cell treatment has achieved great success in clinical trials, especially those in which CAR T cells targeting CD19 have shown excellent response against B-cell lineage hematological malignancies (Scheuermann and Racila, 1995; Porter et al., 2011; Maude et al., 2014; Sommermeyer et al., 2017; Park et al., 2018). Here, CD19 is linked to hematologic disorder.